# Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus

> **NCT03792347** · PHASE1 · COMPLETED · sponsor: **Hecheng Li M.D., Ph.D** · enrollment: 20 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03792347
- **Lead sponsor:** Hecheng Li M.D., Ph.D
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2020-03-17
- **Final completion:** 2020-06-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03792347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03792347, "Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03792347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*